Hematoma growth and outcome in treated neurocritical care patients with intracerebral hemorrhage related to oral anticoagulant therapy: comparison of acute treatment strategies using vitamin K, fresh frozen plasma, and prothrombin complex concentrates
- PMID: 16675739
- DOI: 10.1161/01.STR.0000221786.81354.d6
Hematoma growth and outcome in treated neurocritical care patients with intracerebral hemorrhage related to oral anticoagulant therapy: comparison of acute treatment strategies using vitamin K, fresh frozen plasma, and prothrombin complex concentrates
Abstract
Background and purpose: Intracerebral hemorrhage (ICH) is the most serious and potentially fatal complication of oral anticoagulant therapy (OAT). Still, there are no universally accepted treatment regimens for patients with OAT-ICH, and randomized controlled trials do not exist. The aim of the present study was to compare the acute treatment strategies of OAT-associated ICH using vitamin K (VAK), fresh frozen plasma (FFP), and prothrombin complex concentrates (PCCs) with regard to hematoma growth and outcome.
Methods: In this retrospective study, a total of 55 treated patients were analyzed. Three groups were compared by reviewing the clinical, laboratory, and neuroradiological parameters: (1) patients who received PCCs alone or in combination with FFP or VAK (n=31), (2) patients treated with FFP alone or in combination with VAK (n=18), and (3) patients who received VAK as a monotherapy (n=6). The end points of early hematoma growth and outcome after 12 months were analyzed including multivariate analysis.
Results: Hematoma growth within 24 hours occurred in 27% of patients. Incidence and extent of hematoma growth were significantly lower in patients receiving PCCs (19%/44%) compared with FFP (33%/54%) and VAK (50%/59%). However, this effect was no longer seen between PCC- and FFP-treated patients if international normalized ratio (INR) was completely reversed within 2 hours after admission. The overall outcome was poor (modified Rankin scale 4 to 6 in 77%). Predictors for hematoma growth were an increased INR after 2 hours, whereas administration of PCCs was significantly protective in multivariate analyses. Predictors for a poor outcome were age, baseline hematoma volume, and occurrence of hematoma growth.
Conclusions: Overall, PCC was associated with a reduced incidence and extent of hematoma growth compared with FFP and VAK. This effect seems to be related to a more rapid INR reversal. Randomized controlled trials are needed to identify the most effective acute treatment regimen for lasting INR reversal because increased levels of INR were predisposing for hematoma enlargement.
Similar articles
-
Acute subdural hematoma in patients on oral anticoagulant therapy: management and outcome.Neurosurg Focus. 2017 Nov;43(5):E12. doi: 10.3171/2017.8.FOCUS17421. Neurosurg Focus. 2017. PMID: 29088960
-
Race against the clock: overcoming challenges in the management of anticoagulant-associated intracerebral hemorrhage.J Neurosurg. 2014 Aug;121 Suppl:1-20. doi: 10.3171/2014.8.paradigm. J Neurosurg. 2014. PMID: 25081496 Review.
-
Mortality in vitamin K antagonist-related intracerebral bleeding treated with plasma or 4-factor prothrombin complex concentrate.Thromb Haemost. 2014 Feb;111(2):233-9. doi: 10.1160/TH13-07-0536. Epub 2013 Oct 24. Thromb Haemost. 2014. PMID: 24154891
-
Prothrombin complex concentrates to reverse warfarin-induced coagulopathy in patients with intracranial bleeding.Clin Neurol Neurosurg. 2013 Jun;115(6):770-4. doi: 10.1016/j.clineuro.2012.07.006. Epub 2012 Jul 24. Clin Neurol Neurosurg. 2013. PMID: 22835715
-
Predisposing factors for enlargement of intracerebral hemorrhage in patients treated with warfarin.Thromb Haemost. 2003 Feb;89(2):278-83. Thromb Haemost. 2003. PMID: 12574807 Review.
Cited by
-
Coagulopathy management of multiple injured patients - a comprehensive literature review of the European guideline 2019.EFORT Open Rev. 2022 Oct 26;7(10):710-726. doi: 10.1530/EOR-22-0054. EFORT Open Rev. 2022. PMID: 36287131 Free PMC article. Review.
-
Cerebral Hemorrhage: Pathophysiology, Treatment, and Future Directions.Circ Res. 2022 Apr 15;130(8):1204-1229. doi: 10.1161/CIRCRESAHA.121.319949. Epub 2022 Apr 14. Circ Res. 2022. PMID: 35420918 Free PMC article. Review.
-
Contribution of Various Types of Transfusion to Acute and Delayed Intracerebral Hemorrhage Injury.Front Neurol. 2021 Oct 29;12:727569. doi: 10.3389/fneur.2021.727569. eCollection 2021. Front Neurol. 2021. PMID: 34777198 Free PMC article. Review.
-
Clinical Strategies Against Early Hematoma Expansion Following Intracerebral Hemorrhage.Front Neurosci. 2021 Aug 30;15:677744. doi: 10.3389/fnins.2021.677744. eCollection 2021. Front Neurosci. 2021. PMID: 34526875 Free PMC article. Review.
-
Clinical Outcome in Patients With Intracerebral Hemorrhage Stratified by Type of Antithrombotic Therapy.Front Neurol. 2021 Jun 7;12:684476. doi: 10.3389/fneur.2021.684476. eCollection 2021. Front Neurol. 2021. PMID: 34163431 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical